MULTIDRUG RESISTANT PULMONARY TUBERCULOSIS
Clinical trials for MULTIDRUG RESISTANT PULMONARY TUBERCULOSIS explained in plain language.
Never miss a new study
Get alerted when new MULTIDRUG RESISTANT PULMONARY TUBERCULOSIS trials appear
Sign up with your email to follow new studies for MULTIDRUG RESISTANT PULMONARY TUBERCULOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New TB drug could cut treatment time by two months
Disease control Recruiting nowThis study tests whether a new drug called quabodepistat can shorten treatment for drug-resistant tuberculosis (TB) from 6 months to 4 months. About 532 adults and teens with rifampicin-resistant or multidrug-resistant TB will be randomly assigned to receive either the new shorte…
Matched conditions: MULTIDRUG RESISTANT PULMONARY TUBERCULOSIS
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for Drug-Resistant TB: experimental combo trial launches
Disease control Recruiting nowThis study tests a new drug called JDB0131, combined with other TB medications, in 60 people with rifampin-resistant tuberculosis. Participants will receive one of two doses of JDB0131 or a standard drug (delamanid) for 8 weeks. The goal is to see which combination clears the bac…
Matched conditions: MULTIDRUG RESISTANT PULMONARY TUBERCULOSIS
Phase: PHASE2 • Sponsor: WestVac Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New 2-Month TB pill cocktail could replace 6-Month regimen
Disease control Recruiting nowThis study tests a new ultra-short treatment for both drug-sensitive and drug-resistant tuberculosis (TB). The goal is to see if a 2-3 month regimen works as well as or better than the standard 4-6 month treatment. About 610 adults with active TB will take part. The approach coul…
Matched conditions: MULTIDRUG RESISTANT PULMONARY TUBERCULOSIS
Phase: PHASE3 • Sponsor: Shenzhen Third People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC